COVID-19 Pandemic Vindicates the ISPOR Value Flower
By Kathy Lang, PhD; Jason Shafrin, PhD
PRECISIONheor
What is the right price for a new treatment for COVID-19: ISPOR’s “value flower” or the traditional QALYs approach? Precision’s Jason Shafrin, Kathy Lang and Ross Maclean discuss why the “value flower” model can more accurately value treatments – in cases like COVID-19 – which have a transformational impact on the lives of not only of patients, but also caregivers, employers, and broader society.
